Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lisa Hanner-Robinson

General Practice Bloomington, IN Medical Doctor

NPI 1255336160 CMS profile 102594

1535 S. Piazza Drive, Bloomington, IN 47401

Open in the dashboard

General payments

$8,587

533 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Hanner-Robinson of Bloomington, IN is reported in the CMS Open Payments database as having received $8,587 across 533 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,699 94
2024 General $2,086 118
2023 General $1,507 98
2022 General $1,433 94
2021 General $1,069 69
2020 General $486 50
2019 General $307 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Hanner-Robinson
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Lisa Hanner-Robinson were reported at $1,699. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Lisa Hanner-Robinson General Practice median Middle half National median
2019 $307 $107 $37–$285 $163
2020 $486 $75 $25–$213 $114
2021 $1,069 $93 $30–$272 $132
2022 $1,433 $103 $36–$279 $149
2023 $1,507 $106 $34–$276 $160
2024 $2,086 $114 $39–$290 $164
2025 $1,699 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,066 129 payments
  2. Novo Nordisk Inc $848 54 payments
  3. Lilly USA, LLC $819 61 payments
  4. Pfizer Inc. $424 28 payments
  5. Corcept Therapeutics $403 23 payments
  6. Amgen Inc. $389 24 payments
  7. AstraZeneca Pharmaceuticals LP $343 18 payments
  8. Currax Pharmaceuticals LLC $257 15 payments
  9. Allergan Inc. $252 36 payments
  10. Merz North America, Inc. $244 5 payments
  11. Other $2,541 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,431 526 payments
  2. Education $156 7 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $909 52 payments
  2. QULIPTA $589 32 payments
  3. VRAYLAR $577 48 payments
  4. Ozempic $510 36 payments
  5. RYBELSUS $427 32 payments
  6. Korlym $403 23 payments
  7. EMGALITY $327 21 payments
  8. JARDIANCE $301 22 payments
  9. MOUNJARO $265 21 payments
  10. Wegovy $263 14 payments
  11. Other $5,925 373 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

641

Median for General Practice: 1,105

Drug cost

$32,361

Median for General Practice: $48,734

Branded share of claims

20.4%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 14 $13,450
Mounjaro Tirzepatide Brand 11 $11,910
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 38 $1,063
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $958
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 21 $943
Ezetimibe Generic 17 $554
Gabapentin Generic 24 $381
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 15 $317
Zolpidem Tartrate Generic 30 $276
Levothyroxine Sodium Generic 52 $229

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $201
$201 — —
QULIPTA
  • AbbVie, Inc. $133
$133 — —
NURTEC ODT
  • PFIZER INC. $106
$106 — —
ZEPBOUND
  • Lilly USA, LLC $98
$98 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

533 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record